Last reviewed · How we verify
pandemic vaccine 9
At a glance
| Generic name | pandemic vaccine 9 |
|---|---|
| Also known as | vaccine group F |
| Sponsor | Butantan Institute |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Pain
- Irritability/fussiness
- Muscle aches
- Headache
- Drowsiness
- Fatigue
- Loss of appetite
- Fever (axillary temperature >= 38.0°C)
- Swelling
- Joint pain at other location
- Cough
- Gastrointestinal disorders
Key clinical trials
- A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA) (PHASE1, PHASE2)
- A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine (PHASE2)
- A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers (PHASE1)
- First in Human Phase 1 Ascending Dose Study of PanChol in Healthy Volunteers (PHASE1)
- Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates (NA)
- Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age (PHASE3)
- Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine (PHASE2)
- Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pandemic vaccine 9 CI brief — competitive landscape report
- pandemic vaccine 9 updates RSS · CI watch RSS
- Butantan Institute portfolio CI